Spots Global Cancer Trial Database for VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
Official Title: VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
Study ID: NCT01891708
Interventions
Study Description
Brief Summary: a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer
Detailed Description: 1. non small cell lung cancer (non squamous carcinoma) 2. ECOG 0-1 3. from 18-75 years old
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Contact Details
Name: Li Liu, MD
Affiliation: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
